Experienced in Liposarcoma

Dr. Shiraj Sen

Hematology Oncology | Oncology
Texas Oncology PA
4101 James Casey St, Suite 100, 
Austin, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Liposarcoma
Texas Oncology PA
4101 James Casey St, Suite 100, 
Austin, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Shiraj Sen is a Hematologist Oncology specialist and an Oncologist in Austin, Texas. Dr. Sen is rated as an Experienced provider by MediFind in the treatment of Liposarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Cholangiocarcinoma (Bile Duct Cancer), and Myxoid Liposarcoma. Dr. Sen is currently accepting new patients.

His clinical research consists of co-authoring 34 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article and participated in 1 clinical trial in the study of Liposarcoma.

Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in CO
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Scott and White Health
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

TEXAS ONCOLOGY PA
4101 James Casey St, Suite 100, Austin, TX 78745

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies
Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Biological
Study Phase: Phase 1
A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors
A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Biological
Study Drug: CAB-AXL-ADC
Study Phase: Phase 1/Phase 2
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2025
Intervention Type: Drug
Study Drugs: Letetresgene Autoleucel, Fludarabine, Cyclophosphamide
Study Phase: Phase 2
A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma
A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drugs: GSK3326595, Pembrolizumab
Study Phase: Phase 1
A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: December 24, 2024
Intervention Type: Drug
Study Drug: CYT-0851
Study Phase: Phase 1/Phase 2
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: TSR-033, Dostarlimab, mFOLFOX6, FOLFIRI, Bevacizumab
Study Phase: Phase 1
A Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
A Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Enrollment Status: Completed
Publish Date: April 05, 2024
Intervention Type: Drug
Study Drugs: LY3475070, Pembrolizumab
Study Phase: Phase 1
View 6 Less Clinical Trials

34 Total Publications

Diagnosis, Treatment, and Unmet Needs of Dedifferentiated Liposarcoma in the United States: A Multidisciplinary Delphi Study.
Diagnosis, Treatment, and Unmet Needs of Dedifferentiated Liposarcoma in the United States: A Multidisciplinary Delphi Study.
Journal: Cancers
Published: July 07, 2025
Similar Doctors
Advanced in Liposarcoma
Dr. Rakesh Surapaneni
Hematology Oncology | Hematology | Oncology
Advanced in Liposarcoma
Dr. Rakesh Surapaneni
Hematology Oncology | Hematology | Oncology

Scott And White Clinic

300 University Blvd, 
Round Rock, TX 
 (23.9 miles away)
512-509-0200
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rakesh Surapaneni is a Hematologist Oncology specialist and a Hematologist in Round Rock, Texas. Dr. Surapaneni is rated as a Distinguished provider by MediFind in the treatment of Liposarcoma. His top areas of expertise are Carcinoid Syndrome, Large-Cell Immunoblastic Lymphoma, Upper Tract Urothelial Carcinoma (UTUC), and Thrombocytopenia. Dr. Surapaneni is currently accepting new patients.

Experienced in Liposarcoma
Dr. Michael L. Kasper
Hematology Oncology | Oncology | Hematology
Experienced in Liposarcoma
Dr. Michael L. Kasper
Hematology Oncology | Oncology | Hematology

Texas Oncology PA

6204 Balcones Dr, 
Austin, TX 
 (8.3 miles away)
512-427-9400
Languages Spoken:
English, Spanish, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Kasper is a Hematologist Oncology specialist and an Oncologist in Austin, Texas. Dr. Kasper is rated as an Advanced provider by MediFind in the treatment of Liposarcoma. His top areas of expertise are Multiple Myeloma, Pleuropulmonary Blastoma, Lung Cancer, and Familial Pancreatic Cancer. Dr. Kasper is currently accepting new patients.

Experienced in Liposarcoma
Dr. Christopher D. Braden
Hematology Oncology | Palliative Medicine | Oncology
Experienced in Liposarcoma
Dr. Christopher D. Braden
Hematology Oncology | Palliative Medicine | Oncology

Texas Oncology PA

1448 Common St, 
New Braunfels, TX 
 (39.9 miles away)
830-643-1762
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Christopher Braden is a Hematologist Oncology specialist and a Palliative Medicine provider in New Braunfels, Texas. Dr. Braden is rated as a Distinguished provider by MediFind in the treatment of Liposarcoma. His top areas of expertise are Angiosarcoma, Inflammatory Breast Cancer, Small Lymphocytic Lymphoma (SLL), and Paget Disease of the Breast. Dr. Braden is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sen's expertise for a condition
ConditionClose
      View All 26 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile